Afatinib/erlotinib/gefitinibAcquired resistance in non-small cell lung cancer: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1705卷 / 1期

关键词：

D O I：

10.1007/s40278-018-47032-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：15 / 15

相关论文

共 50 条

[1] Erlotinib/gefitinibAcquired resistance in non-small cell lung cancer: 19 case reports
[J]. Reactions Weekly, 2018, 1711 (1) : 117 - 117
[2] GefitinibAcquired resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2017, 1660 (1) : 164 - 164
[3] Afatinib/gefitinibAcquired drug resistance in non-small cell lung cancer: 3 case reports
[J]. Reactions Weekly, 2021, 1850 (1) : 12 - 12
[4] GefitinibAcquired resistance in metastatic non-small cell lung cancer: case report
[J]. Reactions Weekly, 2020, 1813 (1) : 113 - 113
[5] Erlotinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2020, 1811 (1) : 123 - 123
[6] GefitinibAcquired gefitinib resistnace in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2017, 1655 (1) : 124 - 124
[7] Erlotinib/gefitinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2021, 1850 (1) : 131 - 131
[8] Afatinib/erlotinib/gefitinibDevelopment of resistance to tyrosine kinase inhibitors in non-small cell lung cancer: 123 case reports
[J]. Reactions Weekly, 2021, 1847 (1) : 27 - 27
[9] Afatinib/gefitinibAcquired resistance: case report
[J]. Reactions Weekly, 2023, 1942 (1) : 18 - 18
[10] GefitinibAcquired resistance and adenocarcinoma transformation to small cell lung cancer: case report
[J]. Reactions Weekly, 2015, 1574 (1) : 124 - 124

← 1 2 3 4 5 →